| Identification | Back Directory | [Name]
Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 | [CAS]
102068-15-5 | [Synonyms]
MSI 499
peptide-Gly-Leu-amide
PGLa ion channel-forming peptide
741: PN: US20050058603 SEQID: 736 claimed protein
L-Leucinamide,glycyl-L-methionyl-L-alanyl-L-seryl-L-lysyl-L-alanylglycyl-L-alanyl-L-isoleucyl-L-alanylglycyl-L-lysyl-L-isoleucyl-L-alanyl-L-lysyl-L-valyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl- | [Molecular Formula]
C88H162N26O22S | [MDL Number]
MFCD00273542 | [MOL File]
102068-15-5.mol | [Molecular Weight]
1968.45 |
| Hazard Information | Back Directory | [Uses]
PGLa is a cationic antimicrobial peptide (AMP) originally isolated from frog. It has been shown to have antibacterial,1 antifungal,2 and antiviral,3 activities. It is used to study novel peptide fragments th at originate from PGLa and multinucleated gastric mucosal cells of Xenopus laevis. | [Biological Activity]
The precursors of PGLa are caerulein and xenopsin. The mechanism of action of PGLa against Gram-negative bacteria is disruption of the cellular lipid bilayer.4 It is used to induce transmembrane pore formation in lipid bilayers and bacterial cell membranes. It is used in combination with magainin 2 for a synergistic effect. |
|
|